VRTX Vertex Pharmaceuticals Incorporated
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 12-month channel rising
Price is between the lines.
- 12-month channel
- US$494.45 – US$578.68 · rising, +20% a year
- Price in channel
- 77% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$578.13
- Turns bearish below
- US$493.63
Price history, with the path projected 3 months forward
Updated 10:41 AM ET (49 h ago)
- Daily close
- Upper trend line (12 months)
- Lower trend line (12 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$508.34
level as at 24 Nov 2026
Our target
US$559.18
by 2 Nov 2026
Projected move
10.0%
gross, before costs
Price is between our buy and target.
Target: VRTX's usual move size (10.0%), the best return per day on this path.
This move size: reached in 71% of 9 past stretches, typically in 55 days. (0.18% per day)
- Upper line touches
- 6
- Lower line touches
- 3
- Fit confidence
- 65%
- Fitted
- 1 Nov 2026
Company information
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani
- Employees
- 6,400
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$131.05B
- Enterprise value
- —
- Beta
- 0.32
- Avg volume
- 1.41M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 374.17-560.25
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.